PMID- 26007690
OWN - NLM
STAT- MEDLINE
DCOM- 20160830
LR  - 20221207
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 20
IP  - 6
DP  - 2015 Dec
TI  - Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + 
      carboplatin + docetaxel for advanced upper-tract urothelial cancer.
PG  - 1179-84
LID - 10.1007/s10147-015-0846-z [doi]
AB  - BACKGROUND: Retrospective evaluation of the effectiveness and adverse events 
      (AEs) of a sequential chemotherapy regimen using gemcitabine + carboplatin 
      (GCarbo) followed by GCarbo + docetaxel (GCarboD) for advanced upper-tract 
      urothelial carcinoma (UTUC). METHODS: We treated 56 patients with advanced UTUC. 
      Mean patient age was 68.9 years, creatinine clearance was 51.2 mL/min, and the 
      observation period was 20 months. Patients received two courses of GCarbo 
      comprising 800 mg/m(2) gemcitabine on days 1, 8, and 15, and carboplatin at an 
      area under the curve of four on day 2. If this regimen was effective, we 
      administered two more courses of GCarbo; if the regimen was ineffective, we 
      switched to two courses of GCarboD (70 mg/m(2)). RESULTS: Complete (n = 3) and 
      partial response (PR; n = 25) were achieved after GCarbo. Mean response duration 
      was 9.7 months. Two of 17 cases achieved PR after GCarboD treatment (mean 
      duration, 31.5 months). Median survival was 14.0 months with the GCarbo/GCarboD 
      regimen. Responders to GCarbo therapy survived significantly longer. AEs with the 
      GCarbo regimen included 31 instances of G3/4 blood toxicity and 8 instances of 
      G3/4 urticaria; however, there were only 6 instances of G3/4 gastrointestinal 
      complications. AEs with the GCarboD regimen included 16 instances of blood 
      toxicity and 8 instances of gastrointestinal complications. Neither regimen 
      resulted in G3/4 renal toxicity. CONCLUSIONS: GCarbo and GCarboD chemotherapy may 
      be administered safely to patients with advanced UTUC, with or without renal 
      dysfunction. Response to GCarbo was high (50.0 %) whereas GCarboD was of limited 
      effectiveness for non-responders to GCarbo.
FAU - Yoneyama, Takahiro
AU  - Yoneyama T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan.
FAU - Imai, Atsushi
AU  - Imai A
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan.
FAU - Hatakeyama, Shingo
AU  - Hatakeyama S
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan.
FAU - Hashimoto, Yasuhiro
AU  - Hashimoto Y
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan. bikkuri@opal.plala.or.jp.
FAU - Koie, Takuya
AU  - Koie T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan.
FAU - Ohyama, Chikara
AU  - Ohyama C
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, Aomori, 036-8562, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150526
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Taxoids)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 15H5577CQD (Docetaxel)
RN  - AYI8EX34EU (Creatinine)
RN  - BG3F62OND5 (Carboplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Transitional Cell/*drug therapy/metabolism/pathology
MH  - Creatinine/metabolism
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Docetaxel
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Taxoids/administration & dosage
MH  - Treatment Outcome
MH  - Urologic Neoplasms/*drug therapy/metabolism/pathology
MH  - Gemcitabine
OTO - NOTNLM
OT  - Carboplatin
OT  - Docetaxel
OT  - Gemcitabine
OT  - Upper-urinary tract
OT  - Urothelial carcinoma
EDAT- 2015/05/27 06:00
MHDA- 2016/08/31 06:00
CRDT- 2015/05/27 06:00
PHST- 2015/03/09 00:00 [received]
PHST- 2015/05/04 00:00 [accepted]
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2016/08/31 06:00 [medline]
AID - 10.1007/s10147-015-0846-z [pii]
AID - 10.1007/s10147-015-0846-z [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2015 Dec;20(6):1179-84. doi: 10.1007/s10147-015-0846-z. Epub 
      2015 May 26.